Dehydrocostus Lactone Effectively Alleviates Inflammatory Diseases by Covalently and Irreversibly Targeting NLRP3
Open Access
Abstract
The activation of nucleotide oligomerization domain‐like receptor (NLR) family, pyrin domain‐containing protein 3 (NLRP3) inflammasome is implicated in the pathogenesis of various inflammatory diseases. The natural product oridonin possesses a novel mechanism for NLRP3 inhibition and a unique binding mode with NLRP3, but its poor anti‐inflammatory activity limits further application. After virtual screening of diverse natural product libraries, dehydrocostus lactone (DCL) was considered as a potential NLRP3 inhibitor. DCL effectively inhibited caspase‐1 cleavage and release of IL‐1β in mouse and human macrophages at an extremely low concentration of 10 nM, comparable to MCC950. Mechanistically, our study assigned DCL a novel role in disrupting NLRP3 inflammasome assembly and ASC oligomerization. Excluding the influence on potassium/chloride ion efflux, calcium ion influx, and production of mitochondrial ROS, DCL formed a covalent bond with cysteine 280 in NACHT domain of NLRP3, thereby inhibiting the interaction between NLRP3 and NEK7. Furthermore, DCL exhibited protective effects in mouse models of NLRP3 inflammasome‐mediated diseases, including dextran sulfate sodium‐induced colitis, 2,4,6‐trinitrobenzenesulfonic acid‐induced Crohn's disease, LPS‐induced septic shock, and monosodium urate‐induced peritonitis. Our findings identify NLRP3 as the direct target of DCL, positioning DCL as a promising lead compound for treatment of NLRP3 inflammasome‐related diseases.Keywords
Funding Information
- National Natural Science Foundation of China (U2102201, U24A20785)
This publication has 40 references indexed in Scilit:
- ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)Clinical Microbiology and Infection, 2018
- Tranilast directly targets NLRP3 to treat inflammasome‐driven diseasesEMBO Molecular Medicine, 2018
- Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disordersJournal of Experimental Medicine, 2017
- Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 miceBrain, Behavior, and Immunity, 2017
- β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout FlaresCell Reports, 2017
- 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) increases necroinflammation and hepatic stellate cell activation but does not exacerbate experimental liver fibrosis in miceToxicology and Applied Pharmacology, 2016
- Targeted Covalent Inhibitors for Drug DesignAngewandte Chemie International Edition, 2016
- Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanismJournal of Leukocyte Biology, 2015
- A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseasesNature Medicine, 2015
- The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory diseaseNature Medicine, 2015